Andrea Duminuco - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Andrea Duminuco

Showing results (71-80 of 73) with videos related to

Pageof 8

Sort By:

You have reached the last page of results.This site can display upto 73 results.

Cancer|July 30, 2024

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.

Leukemia|March 28, 2026

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomesLaura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.

Cancer|May 12, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.

Pageof 8

Search research articles

Showing results (71-80 of 73) with videos related to

Sort By:

Pageof 8

You have reached the last page of results.This site can display upto 73 results.

Cancer|July 30, 2024

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.

Leukemia|March 28, 2026

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomesLaura Li Gagnon, Andrea Duminuco, Fabio Stagno, et al.

Cancer|May 12, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.

Pageof 8